PainReform (NASDAQ:PRFX) Stock Price Up 0.4% – Here’s What Happened

PainReform Ltd. (NASDAQ:PRFX) rose 0.4% during trading on Wednesday . The company traded as high as $0.7698 and last traded at $0.7359. Approximately 140,746 shares changed hands during trading, a decline of 97% from the average daily volume of 4,605,139 shares. The stock had previously closed at $0.7330.

Wall Street Analysts Forecast Growth

PRFX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of PainReform from a “strong sell” rating to a “hold” rating in a research note on Friday, October 3rd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, PainReform presently has a consensus rating of “Sell”.

PainReform Price Performance

The firm has a market capitalization of $1.48 million, a PE ratio of 0.00 and a beta of 0.59. The company’s fifty day simple moving average is $0.87 and its 200 day simple moving average is $1.19.

PainReform (NASDAQ:PRFX) last posted its earnings results on Wednesday, October 1st. The company reported ($0.55) earnings per share for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.